These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 23574329)

  • 1. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease.
    Tobin LM; Healy ME; English K; Mahon BP
    Clin Exp Immunol; 2013 May; 172(2):333-48. PubMed ID: 23574329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
    Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
    Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
    Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
    Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
    Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
    Front Immunol; 2019; 10():619. PubMed ID: 31001253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel study on the immunomodulatory effect of umbilical cord derived mesenchymal stem cells pretreated with traditional Chinese medicine Asarinin.
    He H; Yang T; Li F; Zhang L; Ling X
    Int Immunopharmacol; 2021 Nov; 100():108054. PubMed ID: 34492537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased splenic human CD4
    Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
    Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human T cells depend on functional calcineurin, tumour necrosis factor-α and CD80/CD86 for expansion and activation in mice.
    Søndergaard H; Kvist PH; Haase C
    Clin Exp Immunol; 2013 May; 172(2):300-10. PubMed ID: 23574326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced alleviation of aGVHD by TGF-β1-modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells.
    Wu R; Liu C; Deng X; Chen L; Hao S; Ma L
    J Cell Mol Med; 2020 Jan; 24(2):1684-1699. PubMed ID: 31782262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.
    Trujillo-Ocampo A; Cho HW; Herrmann AC; Ruiz-Vazquez W; Thornton AB; He H; Li D; Qazilbash MA; Ma Q; Porcelli SA; Shpall EJ; Molldrem J; Im JS
    Cytotherapy; 2018 Aug; 20(8):1089-1101. PubMed ID: 30076070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
    Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
    Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation.
    Wu N; Liu R; Liang S; Gao H; Xu LP; Zhang XH; Liu J; Huang XJ
    Front Immunol; 2021; 12():687961. PubMed ID: 34335589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
    Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
    PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
    Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.